4
Changes in Ownership
Adaptimmune Therapeutics PLC Filed Acc 0001104659-19-002166
Chief Technology Officer sold 1,514 shares at $5.37 ($8,129)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Binder-Scholl Gwendolyn Knowlton Chief Technology Officer | 2019-01-14 | Sale | −1,514 | $5.37 | $8,129 | 2,487 | D: show line 1 in the form |
| Open-market sales · 1,514 sh · avg $5.37 · $8,129 | |||||||
Loading xslF345X03/a4.xml…